Drug eases GVHD symptoms in patients who had stem cell transplant

12/1/2011 | U.S. News & World Report

Daily, low-dose injections of interleukin-2 eased symptoms of graft-versus-host disease, or GVHD, in cancer patients who underwent allogeneic hematopoietic stem cell transplantation, according to a study published in the New England Journal of Medicine. Of 23 patients given the drug for eight weeks, 12 showed improvement, according to the study.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC